QHSLab (OTCQB:USAQ) Reports Strong Fiscal 2025 Results with Revenue Growth, Expanding Margins, and Significant Balance Sheet Improvement

Core Insights - The company reported significant revenue growth and improved profitability for fiscal year 2025, driven by the expansion of its Integrated Service Program (ISP) and operational improvements [1][4][12] Financial Highlights - Total revenue increased to $2,691,741 in 2025, a growth of approximately 26% compared to $2,131,926 in 2024 [8] - Gross profit rose to $1,810,849, with gross margin expanding to 67.3% from 63.7% in the previous year [8] - Net income improved to $457,417 in 2025, contrasting with a net loss of $259,239 in 2024 [8] - Interest expense significantly declined to $237,413 from $465,055 in 2024 due to debt restructuring [8] - The company recorded a gain of approximately $1.15 million related to the extinguishment of convertible debt, enhancing the balance sheet [8] Operational Highlights - The ISP revenue surged by 74% year-over-year to $1,121,134, indicating strong adoption among primary care providers [4] - Sales of immunotherapy treatments increased by approximately 19% year-over-year, contributing to revenue diversification [5] - The company operates a growing portfolio of healthcare solutions, including digital health decision-support tools and allergy diagnostics, which support primary care physicians in managing chronic conditions [6] Management Commentary - The President and CEO highlighted 2025 as a year of operational progress and financial strengthening, emphasizing the importance of the ISP as a long-term growth driver [7] - The company aims to expand its physician network and scale its digital health infrastructure in 2026 [7]